Novo Nordisk

Explore information and tools designed to help you support your patients.

Man on rocks with speech bubbles: 'Painful administration' and 'High volume injections' Text reads 'Thanks for signing up.'

You have taken the first step in understanding the trade-offs that hemophilia A patients face on a daily basis. Stay tuned for more information from Novo Nordisk that may impact your patients.^2,3

Visit our Administration Challenges page to better understand the challenges your patients face.

Access now

References:

1.	Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996.
2.	Data on file. Novo Nordisk Inc; Plainsboro, NJ.
3.	Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia, 2021;27(4):699]. Haemophilia, 2020;26(suppl 6):1-158.

Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement.